1.15Open0.75Pre Close5 Volume195 Open Interest290.00Strike Price575.00Turnover46.77%IV15.07%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry1.15Extrinsic Value100Contract SizeAmericanOptions Type0.1048Delta0.0070Gamma202.41Leverage Ratio-0.1352Theta0.0122Rho21.21Eff Leverage0.1010Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet